Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Kjekshus

Showing results (51-60 of 112) with videos related to

Pageof 12
Sort By:
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 22, 2016
Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)Fizza Arain, Lars Gullestad, Ståle Nymo, et al.
The American Journal of Cardiology|January 13, 2004
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)Cynthia J Girman, Thomas Rhodes, Michele Mercuri, et al.
European Heart Journal|April 23, 2009
Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trialStefan D Anker, Adriaan Voors, Darlington Okonko, et al.
Circulation. Heart Failure|November 29, 2013
Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trialJørgen Gravning, Erik T Askevold, Ståle H Nymo, et al.
Journal of the American College of Cardiology|January 18, 2005
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)Lars Gullestad, John Wikstrand, Prakash Deedwania, et al.
Diabetes Care|June 29, 2004
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)Kalevi Pyörälä, Christie M Ballantyne, Barry Gumbiner, et al.
Journal of the American College of Cardiology|November 16, 2004
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarctionThor Ueland, Rune Jemtland, Kristin Godang, et al.
Journal of Cardiac Failure|October 19, 2006
Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarctionThor Ueland, Terje Espevik, John Kjekshus, et al.
European Journal of Heart Failure|February 17, 2015
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HFMatthew J Feinstein, Pardeep Jhund, Joseph Kang, et al.
Transplantation|November 27, 2002
Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertensionTorbjørn Holm, Pål Aukrust, Erik Aagaard, et al.
Pageof 12

Showing results (51-60 of 112) with videos related to

Sort By:
Pageof 12
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|June 22, 2016
Low YKL-40 in chronic heart failure may predict beneficial effects of statins: analysis from the controlled rosuvastatin multinational trial in heart failure (CORONA)Fizza Arain, Lars Gullestad, Ståle Nymo, et al.
The American Journal of Cardiology|January 13, 2004
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)Cynthia J Girman, Thomas Rhodes, Michele Mercuri, et al.
European Heart Journal|April 23, 2009
Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trialStefan D Anker, Adriaan Voors, Darlington Okonko, et al.
Circulation. Heart Failure|November 29, 2013
Prognostic effect of high-sensitive troponin T assessment in elderly patients with chronic heart failure: results from the CORONA trialJørgen Gravning, Erik T Askevold, Ståle H Nymo, et al.
Journal of the American College of Cardiology|January 18, 2005
What resting heart rate should one aim for when treating patients with heart failure with a beta-blocker? Experiences from the Metoprolol Controlled Release/Extended Release Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF)Lars Gullestad, John Wikstrand, Prakash Deedwania, et al.
Diabetes Care|June 29, 2004
Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S)Kalevi Pyörälä, Christie M Ballantyne, Barry Gumbiner, et al.
Journal of the American College of Cardiology|November 16, 2004
Prognostic value of osteoprotegerin in heart failure after acute myocardial infarctionThor Ueland, Rune Jemtland, Kristin Godang, et al.
Journal of Cardiac Failure|October 19, 2006
Mannose binding lectin and soluble Toll-like receptor 2 in heart failure following acute myocardial infarctionThor Ueland, Terje Espevik, John Kjekshus, et al.
European Journal of Heart Failure|February 17, 2015
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HFMatthew J Feinstein, Pardeep Jhund, Joseph Kang, et al.
Transplantation|November 27, 2002
Hypertension in relation to nitric oxide, asymmetric dimethylarginine, and inflammation: different patterns in heart transplant recipients and individuals with essential hypertensionTorbjørn Holm, Pål Aukrust, Erik Aagaard, et al.
Pageof 12